Roy L Maute, Sydney R Gordon, Aaron T Mayer, Melissa N McCracken, Arutselvan Natarajan, Nan Guo Ring, Richard Kimura, Jonathan M Tsai, Aashish Manglik, Andrew C Kruse, Sanjiv S Gambhir, Irving L Weissman, Aaron M Ring
Signaling through the immune checkpoint programmed cell death protein-1 (PD-1) enables tumor progression by dampening antitumor immune responses. Therapeutic blockade of the signaling axis between PD-1 and its ligand programmed cell death ligand-1 (PD-L1) with monoclonal antibodies has shown remarkable clinical success in the treatment of cancer. However, antibodies have inherent limitations that can curtail their efficacy in this setting, including poor tissue/tumor penetrance and detrimental Fc-effector functions that deplete immune cells...
November 24, 2015: Proceedings of the National Academy of Sciences of the United States of America